| __timestamp | Halozyme Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 179279000 |
| Thursday, January 1, 2015 | 29245000 | 186359000 |
| Friday, January 1, 2016 | 33206000 | 171785000 |
| Sunday, January 1, 2017 | 31152000 | 208136000 |
| Monday, January 1, 2018 | 10136000 | 198405000 |
| Tuesday, January 1, 2019 | 45546000 | 224169000 |
| Wednesday, January 1, 2020 | 43367000 | 245044000 |
| Friday, January 1, 2021 | 81413000 | 252314000 |
| Saturday, January 1, 2022 | 139304000 | 268225000 |
| Sunday, January 1, 2023 | 192361000 | 304629000 |
| Monday, January 1, 2024 | 159417000 | 324203000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro consistently maintained a higher cost of revenue, peaking at approximately 304 million in 2023, a 70% increase from 2014. In contrast, Halozyme's cost of revenue surged by over 740% during the same period, reaching around 192 million in 2023. This stark contrast highlights Taro's stable yet high expenditure, while Halozyme's rapid growth trajectory suggests aggressive expansion strategies. Notably, data for 2024 is incomplete, indicating potential shifts in the coming year. Understanding these trends is crucial for investors and stakeholders aiming to navigate the competitive landscape of pharmaceutical manufacturing.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Biogen Inc. vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Taro Pharmaceutical Industries Ltd. and Viridian Therapeutics, Inc.'s Expenses